#France #Lyon #genOway #Antibody Therapy #FcγR Model

Transforming Antibody Therapy Predictions with genOway

In the realm of modern medicine, antibody therapies are making a significant impact on the treatment of cancers, inflammatory diseases, and infections. Despite their promise, many potential drug candidates fail during clinical trials, leading to delays in patient access to innovative treatments. A recent study published in Science Immunology highlights an innovative mouse model developed by genOway called genO-hFcγR that provides more accurate predictions of antibody efficacy and safety in humans.

Why Do Antibody Therapies Fail?

Antibody therapies exert their effects through interactions with Fcγ receptors that are present on immune cells. These receptors play crucial roles in immune functions, including antibody-mediated cell death and inflammation. However, because these receptors differ across species, testing human therapeutic antibodies in standard laboratory mice often yields unreliable efficacy data and fails to identify potential safety risks. Such discrepancies lead to costly failures in late-stage trials and slow down access to new therapies for patients in need.

Revolutionary Model for Antibody Therapy

The genO-hFcγR mouse model developed by genOway allows researchers to better predict how therapeutic antibodies will perform in humans. This model not only enables scientists to classify and evaluate different antibodies based on their potential effectiveness but also helps in assessing their ability to engage specific immune cell types and slow disease progression. Such insights are critical for guiding decisions in research and accelerating drug development processes.

Features of the genO-hFcγR Model

1. Enhanced Predictive Value: The model provides a more accurate simulation of human immune responses, helping in the identification of the most promising antibody candidates early in the research phase.
2. Multi-Faceted Approach: It enables researchers to study multiple factors related to antibody efficacy and safety simultaneously, which is often a challenge in conventional models.
3. Support for Studies on Disease Progression: The model empowers researchers to evaluate the potential of therapeutic antibodies in addressing the underlying mechanisms of diseases, paving the way for tailored treatments.

Collaboration in Science

Creating the genO-hFcγR model required a diverse range of expertise from across the globe, encompassing mouse genetics, antibody biology, and human immunology. This achievement was made possible through a consortium of leading biopharmaceutical partners, spearheaded by genOway. The consortium included argenx (Belgium), Innate Pharma (France), Vir Biotechnology (USA), and more. They collaborated with VIB-Ghent University (Belgium), a prominent immunology institute, in mapping receptor expression and elucidating how the new mouse model can more accurately simulate human diseases.

Broad Adoption of an Innovative Tool

The genO-hFcγR model builds upon a previous mouse model developed by genOway in 2008, which focused on humanizing multiple FcγR genes. Since making this new model available to the scientific community in 2024, it has been adopted in preclinical programs by various biopharmaceutical companies and nonprofit organizations, including the Gates Foundation as part of its global health research initiatives.

For further details on the study and model, you can view the publication here.

About genOway

Founded with a mission to advance medical research, genOway is a biotechnology company offering highly predictive preclinical models and solutions to biopharmaceutical companies, CROs, and academic institutions. Their goal is to facilitate the transition from laboratory findings to clinical success, thereby enhancing the drug development landscape.